A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Inclusion Criteria

• •Cohort A: Patients greater than or equal to (\>/=) 12 years of age at time of informed consent
• •Cohort A: Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is, \>/= 5 Bethesda units \[BU\])
• •Cohort B: Pediatric patients less than (\<) 12 years of age
• •Cohort B: Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is, \>/=5 BU)
• •Cohort C: Patients \>/=12 years of age
• •Cohort C: Diagnosis of congenital hemophilia A and FVIII activity \<1 percent (%)
• •Cohort C: No prior history of a positive inhibitor against FVIII